Filing search / Fusion Pharmaceuticals Inc / "Benefits"

8-K

EX-99.1

FUSN Fusion Pharmaceuticals Inc

4 Jun 24

Acquisition of Fusion Pharmaceuticals Completed

4:18pm

; and the failure to realize the expected benefits of the Arrangement. Please also refer to the factors discussed under “Risk Factors” and “Special Note

DEFA14A

FUSN Fusion Pharmaceuticals Inc

10 May 24

Additional proxy soliciting materials

4:15pm

into, the anticipated benefits of the Arrangement for Fusion and its Shareholders, and whether the Milestone under the CVR Agreement will be achieved. Fusion’s … as a result of the announcement and pendency of the Arrangement; significant transaction costs; the failure to realize the expected benefits of the Arrangement

8-K

FUSN Fusion Pharmaceuticals Inc

10 May 24

Other Events

7:54am

Agreement) will be entered into, the anticipated benefits of the Arrangement for Fusion and its Shareholders, and whether the Milestone under the CVR … the expected benefits of the Arrangement; risks associated with the disruption of management’s attention from ongoing business operations due

8-K

EX-99.1

FUSN Fusion Pharmaceuticals Inc

7 May 24

Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates

7:30am

. The development plan includes a Phase 2 dose optimization lead-in, which aims to evaluate whether there are added safety and/or efficacy benefits of various … the CVR Agreement (as defined in the Arrangement Agreement) will be entered into, the anticipated benefits of the proposed transaction for Fusion

DEFA14A

bih6w m8jt

2 May 24

Additional proxy soliciting materials

7:54am

8-K

5x24sp9igajwcp fz

2 May 24

Other Events

7:52am

DEFM14A

e2l 4g1cf9jb5h

25 Apr 24

Proxy related to merger

4:13pm

DEFA14A

qgobnch5

23 Apr 24

Additional proxy soliciting materials

7:36am

8-K

zzkf qbd5t

23 Apr 24

Other Events

7:34am

PREM14A

p4n9rzqdverp

10 Apr 24

Preliminary proxy related to merger

4:42pm

8-K

EX-99.1

rqwbh0z0e4

20 Mar 24

Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates

4:10pm

DFAN14A

ec1rzx

19 Mar 24

Additional proxy materials by non-management

5:27pm

DEFA14A

6qhmm fnq4b

19 Mar 24

Additional proxy soliciting materials

6:25am

8-K

EX-10.1

g0be30twyzcs

19 Mar 24

Voting and Support Agreement

6:24am

8-K

2cl lwy3e5q0t6yy4wyt

19 Mar 24

Voting and Support Agreement

6:24am

8-K

EX-99.2

l3d swhrpnyspzpf

19 Mar 24

Voting and Support Agreement

6:24am